UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041813
Receipt number R000047720
Scientific Title Prospective observational study of cancer-cachexia and its effect on chemotherapy in patients with previously-untreated advanced non-small cell lung cancer (NEJ050A)
Date of disclosure of the study information 2020/09/16
Last modified on 2023/09/19 17:27:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective observational study of cancer-cachexia and its effect on chemotherapy in patients with previously-untreated advanced non-small cell lung cancer (NEJ050A)

Acronym

Prospective observational study of cancer-cachexia in patients with previously-untreated advanced non-small cell lung cancer (NEJ050A)

Scientific Title

Prospective observational study of cancer-cachexia and its effect on chemotherapy in patients with previously-untreated advanced non-small cell lung cancer (NEJ050A)

Scientific Title:Acronym

Prospective observational study of cancer-cachexia in patients with previously-untreated advanced non-small cell lung cancer (NEJ050A)

Region

Japan


Condition

Condition

Non-small cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate decline in quality of life (QOL) about appetite during chemotherapy, adverse events and efficacy of chemotherapy in previously-untreated advanced non-small cell lung cancer with cancer-cachexia.
To elucidate the frequency of cancer-cachexia in previously-untreated advanced non-small cell lung cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Transition of FAACT (A/CS) during chemotherapy

Key secondary outcomes

Questionnaire for eating-related distress among patients with advanced cancer (QERD), Care Notebook, FACT-G, anchor questionnaire, ECOG PS, KPS, body weight, objective response rate, disease control rate, progression-free survival, overall survival, adverse events, minimally important difference in QERD, validation of QERD, proportion of cachexia


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Pathologically diagnosed NSCLC.
(2) Newly diagnosed locally advanced (clinical stage IIIB, IIIC) or metastatic NSCLC
(clinical stage IVA or IVB) or recurrent NSCLC, not amenable to curative surgery or radiotherapy
(3) Patients who have cachexia (meet one of the following (i) or (ii); (i) weight loss > 5% within the last 6 months, (i) BMI < 20 and weight loss > 2% within the last 6 months).
(4) No prior systemic treatment with systemic anti-cancer therapy for advanced NSCLC. Subjects who received prior adjuvant and/or neo-adjuvant therapies are eligible.
(5) Subjects scheduled to receive chemotherapy.
(6) ECOG PS of 0 to 2.
(7) Aged 20 years or more.
(8) Provided Informed Consent.

Key exclusion criteria

(1) Current use of corticosteroids.
(2) Subjects scheduled to receive treatment, but don't fit into cohorts 1, 2, or 3.
(3) Subjects who are unable to accurately complete the QOL questionnaire.
(4) Subjects who are judged by the principal or sub-investigator to be unsuitable for inclusion in this study.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Kazuhisa
Middle name
Last name Takahashi

Organization

Juntendo University Graduate School of Medicine

Division name

Department of Respiratory Medicine

Zip code

113-8421

Address

2-1-1, Hongo, Bunkyo-ku, Tokyo

TEL

03-3813-3111

Email

kztakaha@juntendo.ac.jp


Public contact

Name of contact person

1st name Keita
Middle name
Last name Miura

Organization

Juntendo University Graduate School of Medicine

Division name

Department of Respiratory Medicine

Zip code

113-8421

Address

2-1-1, Hongo, Bunkyo-ku, Tokyo

TEL

03-3813-3111

Homepage URL


Email

k-miura@juntendo.ac.jp


Sponsor or person

Institute

North East Japan Study Group (NEJSG)

Institute

Department

Personal name



Funding Source

Organization

ONO PHARMACEUTICAL CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Juntendo University Hospital Independent Ethics Committee

Address

3-1-3, Hongo, Bunkyo-ku, Tokyo

Tel

03-5802-1584

Email

kenkyu5858@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 09 Month 16 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

186

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2020 Year 09 Month 11 Day

Date of IRB

2020 Year 09 Month 11 Day

Anticipated trial start date

2020 Year 11 Month 30 Day

Last follow-up date

2022 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Prospective observational study


Management information

Registered date

2020 Year 09 Month 16 Day

Last modified on

2023 Year 09 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047720


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name